film roulette

film roulette

NoneNone

The traditional holiday movie launch may be getting supplanted by blockbuster video games, with major interactive releases increasingly taking up prime advertising space and drawing consumer dollars. There have been examples of video games out-grossing the box office since the ’90s. Culturally, films have been thought of as a group entertainment activity, while games have been regarded as more of a gift to put under the tree for kids and game fans. A new study suggests that’s shifting. An ad for holiday blockbuster game Indiana Jones and the Great Circle on a Melbourne tram. Credit: Simon Schluter About three in five adult Australians play games, and more than half of the population intends to make a gaming-related purchase as part of their holiday spending, according to the survey conducted by YouGov. Of those people, the average anticipated spend was about $200, whereas Australians in general anticipated spending about $82 at the cinema. Millennials were expected to be the highest spenders, with the largest proportion of that age group planning to spend up to $250 on gaming purchases over the holiday period. The survey, commissioned by Xbox, also found that more than half of adult Australians prioritised games in their holiday entertainment, and that 61 per cent of families with children agreed gaming was a bonding family tradition. Xbox Australia’s games lead Eve Oorloff said the medium was becoming more of a shared holiday experience, as families increasingly have multiple generations of game-players. “This shift in perception is really encouraging, as more people are beginning to see the value of gaming in bringing people together, much like the movies have done for generations,” she said. “We love being at the forefront of this continued evolution and adoption of gaming across generations, and watching it become a shared experience between players.” Telsyte analyst Foad Fadaghi, who was not involved in the research, said video games are appealing as gifts and activities when families are looking to maximise value in terms of dollars spent per hour of entertainment. A trip to the cinema with the whole family can easily cost as much as the most expensive new game. “According to everything we’ve seen, there’s been a shift against that kind of retail spending. People are spending a lot more time at home for their entertainment,” he said. “Entertainment is always a function of discretionary income, and clearly families see a lot of value in games.” Xbox says families are increasingly playing video games together as a holiday tradition. New games for this holiday period include Indiana Jones and the Great Circle and Call of Duty Black Ops 6 , both published by Microsoft-owned studios, as well as Astro Bot , Lego Horizon Adventures , Super Mario Party Jamboree and Sonic X Shadow Generations . Microsoft’s own games are included in its Game Pass Ultimate subscription service – meaning families could also play Indiana Jones and hundreds of other games for $23 a month, roughly the price of a movie ticket – on Xbox consoles or on PCs, which the study indicated were used for gaming by about half the playing population. But Fadaghi said the increased digitisation of the games marketplace came with certain dangers for game sales, especially at Christmas. Digital gifts are available but might not be preferred by family members who want to wrap up a present, and games could become less favourable as a gift if the trend towards subscriptions continue. In the era of Netflix, few people get DVDs as a gift. Harrison Ford has been digitally recreated as he looked in 1980 for The Great Circle, a globe-spanning, fascist-punching adventure set just after Raiders of the Lost Ark. “Subscriptions represent great value for money. But they represent an ongoing payment, so for some people it’s a little bit different from that one-off gift,” he said. The YouGov study indicated that, of the people who intended to make a gaming purchase these holidays, about two in five expected to buy a gift card or voucher. Loading Oorloff said Xbox invested in a wide variety of games to enhance the value of Game Pass, but Hollywood-style release campaigns were still vital for blockbuster games, which take many years and millions of dollars to make. “Making a splash at launch helps capture interest and build momentum and awareness. It also sets the title up for ongoing success through fan engagement with downloadable content, updates, expansions, and community events,” she said. “Games offer rich narratives, cinematic experiences, and interactive storytelling that rival any Hollywood production; the launch of a hotly anticipated title can feel similar to a movie premiere.” Get news and reviews on technology, gadgets and gaming in our Technology newsletter every Friday. Sign up here. Save Log in , register or subscribe to save articles for later. License this article Video games For subscribers Tim Biggs is a writer covering consumer technology, gadgets and video games. Connect via Twitter or email . Most Viewed in Technology Loading‘Wheel of Fortune’ Player Misses $40,000 Win After Disney DisasterMark Few likes No. 3 Gonzaga's toughness after win over future Pac-12 'partner' SDSU

AP Business SummaryBrief at 10:21 a.m. ESTHouse blocks release of Matt Gaetz ethics reportWalmart (NYSE:WMT) Given New $100.00 Price Target at Robert W. Baird

Cops probing human remains discovery at Henley, St JohnMaverick McNealy birdies the last hole at Sea Island to finally become PGA Tour winner

WASHINGTON (AP) — American Airlines briefly grounded flights nationwide Tuesday due to a technical issu e just as the Christmas travel season kicks into overdrive and winter weather is threatening more potential problems for those planning to fly or drive. American flights were cleared to fly by federal regulators about one hour after a national ground stop order was issued by the Federal Aviation Administration. There were 1,447 delays for flights entering or leaving the U.S. early in the day, with 28 cancellations. Snow was falling early in New York and Dallas-Fort Worth International, which is American Airlines' main hub, was getting hit with rain. Dallas-Fort Worth had the most delays, followed by Charlotte, North Carolina, Washington, New York, Chicago and Miami Because the holiday travel period lasts weeks, airports and airlines typically have smaller peak days than they do during the rush around Thanksgiving, but the grind of one hectic day followed by another takes a toll on flight crews. And any hiccups — a winter storm or a computer outage — can snowball into massive disruptions. That is how Southwest Airlines stranded 2 million travelers in December 2022, and Delta Air Lines suffered a smaller but significant meltdown after a worldwide technology outage in July caused by a faulty software update from cybersecurity company CrowdStrike. Many flights during the holidays are sold out, which makes cancellations even more disruptive than during slower periods. That is especially true for smaller budget airlines that have fewer flights and fewer options for rebooking passengers. Only the largest airlines, including American, Delta and United, have “interline agreements” that let them put stranded customers on another carrier’s flights. This will be the first holiday season since a Transportation Department rule took effect that requires airlines to give customers an automatic cash refund for a canceled or significantly delayed flight. Most air travelers were already eligible for refunds, but they often had to request them. Passengers still can ask to get rebooked, which is often a better option than a refund during peak travel periods. That’s because finding a last-minute flight on another airline yourself tends to be very expensive. Just before 7 a.m. Eastern time, the Federal Aviation Administration ordered all American Airlines flights grounded in the U.S. at the airline’s request. American had reported a technical issue affecting its entire system with millions traveling for the holiday. American said in an email that the problem Tuesday morning was caused by a vendor technology issue that “impacted systems needed to release flights.” The groundings couldn’t come at a worse time for the millions of travelers expected to fly over the next 10 days. The Transportation Security Administration expects to screen 40 million passengers over the holidays and through January 2. Airlines expect to have their busiest days on Friday and Sunday, and on Dec. 26, Dec. 27 and Dec. 29. Many flights during the holidays are sold out, which makes cancellations more disruptive than during slower periods. Even with just a brief outage, the cancellations have a cascading effect that can take days to clear up. About 90% of Americans traveling far from home over the holidays will be in cars, according to AAA. “Airline travel is just really high right now, but most people do drive to their destinations, and that is true for every holiday,” AAA spokesperson Aixa Diaz said. Gasoline prices are similar to last year. The nationwide average Thursday was $3.04 a gallon, down from $3.13 a year ago, according to AAA. Charging an electric vehicle averages just under 35 cents per per kilowatt hour, but varies by state. Transportation-data firm INRIX says travel times on the nation’s highways could be up to 30% longer than normal over the holidays, with Sunday expected to see the heaviest traffic. Boston, New York City, Seattle and Washington, D.C., are the metropolitan areas primed for the greatest delays, according to the company. —— AP Reporters David Koenig, Mae Anderson and Mike Pesoli contributed to this report.About Marvell To deliver the data infrastructure technology that connects the world, we're building solutions on the most powerful foundation: our partnerships with our customers. Trusted by the world's leading technology companies for over 25 years, we move, store, process and secure the world's data with semiconductor solutions designed for our customers' current needs and future ambitions. Through a process of deep collaboration and transparency, we're ultimately changing the way tomorrow's enterprise, cloud, automotive, and carrier architectures transform—for the better. Marvell® and the Marvell logo are registered trademarks of Marvell and/or its affiliates. For further information, contact: Ashish Saran Senior Vice President, Investor Relations 408-222-0777 ir@marvell.com View original content to download multimedia: https://www.prnewswire.com/news-releases/marvell-technology-inc-declares-quarterly-dividend-payment-302331636.html SOURCE Marvell

Global Visual Thinking Software Market Size, Share and Forecast By Key Players-Mind Technologies AS, Mindjet, Mural, Ayoa, MatchWare

Man accused in burning death of a woman on New York subway appears in courtAmerican Battery Technology Company: Give Your Portfolio A Boost

100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy 1 , 2 BEERSE, BELGIUM, Dec. 08, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI ® ▼ (teclistamab) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and maintenance settings. 1 , 2 The MajesTEC-5 (Abstract #493) and MajesTEC-4 (Abstract #494) studies establish the potential of teclistamab for use in newly diagnosed patients, with promising efficacy and a tolerable safety profile. 1 , 2 These data were highlighted as oral presentations at the 2024 American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, California, United States from 7-10 December. 1 , 2 Forty-nine patients with transplant-eligible NDMM were treated with teclistamab in combination with DARZALEX ® (daratumumab) subcutaneous (SC) formulation, lenalidomide and dexamethasone (Tec-DRd) or daratumumab SC, bortezomib, lenalidomide and dexamethasone (Tec-DVRd) as induction therapy in the MajesTEC-5 study. 1 All patients who were evaluated for MRD negativity after cycle 3 of induction therapy achieved MRD negativity (10 -5 ) and maintained through cycle 6. 1 "These data from the MajesTEC-5 study build on the growing body of evidence of teclistamab combinations that support the potential combinability of teclistamab with other effective therapies, demonstrating high rates of MRD-negative responses for evaluable patients with newly diagnosed multiple myeloma,” said Rachel Kobos, M.D., Vice President, Oncology Research & Development, Johnson & Johnson Innovative Medicine. "At Johnson & Johnson, our deep expertise and understanding of multiple myeloma has shaped the regimens we're developing, including our bispecific antibodies in new combinations, and we're committed to exploring the full potential of our therapies to improve outcomes for patients.” The safety profiles were manageable and consistent with individual safety profiles. 1 No treatment-emergent adverse events (TEAEs) led to study treatment discontinuation or death; cytokine release syndrome (CRS; Grade 1 or 2) occurred in 65 percent of patients. 1 No patients experienced immune effector cell-associated neurotoxicity syndrome (ICANS). 1 Grade 3/4 TEAEs included lymphopenia (43 percent), neutropenia (57 percent) and infections (35 percent). 1 "There remains opportunity to achieve even deeper and more sustained outcomes for a broader patient population in the frontline setting,” said Marc S. Raab, M.D., Heidelberg University Hospital, Germany.* "These data reinforce the potential of teclistamab when used in earlier lines and show that teclistamab can be leveraged to optimise existing standard regimens in combination.” Results from the safety run-in of the Phase 3 MajesTEC-4 study highlighted the potential of teclistamab to be administered as a maintenance therapy following autologous stem cell transplant (ASCT). 2 MajesTEC-4 is the first study to present data on a B-cell maturation antigen (BCMA) bispecific as monotherapy or combination therapy after ASCT. 2 Low rates of non-haematologic Grade 3/4 TEAEs and discontinuation of treatment due to all TEAEs (5.3 percent) were observed. 2 CRS events were all Grade 1/2, mostly occurring during step-up dosing, and ICANS was not observed. 2 Neutropenia and infections were the most common Grade 3/4 TEAEs. 2 Grade 3/4 neutropenia at 6 months showed a decreased trend in cohorts 2 and 3 with less frequent teclistamab dosing (cohort 1: 94 percent, cohort 2: 63 percent, cohort 3: 47 percent). 2 A similar trend was observed for all-grade infections (cohort 1: 94 percent; cohort 2: 78 percent; cohort 3: 77 percent). 2 All evaluable patients in cohort 1 who underwent MRD assessment after 12 months of therapy were MRD negative, and 100 percent of evaluable patients assessed in cohorts 2 and 3 were also MRD negative at cycle 6. 2 Further analysis of combination therapies will be evaluated in the Phase 3 MajesTEC-7 study which is currently enrolling. 3 "Teclistamab was the first BCMA bispecific therapy approved as monotherapy for relapsed and refractory multiple myeloma and plays an important role in our approach to transform outcomes for all people living with this complex disease,” said Edmond Chan, MBChB, M.D. (Res), EMEA Therapeutic Area Lead Hematology, Johnson & Johnson Innovative Medicine. "The deep MRD negativity results achieved by teclistamab in earlier lines and in combination with established regimens, including daratumumab, reinforce the potential of this transformative therapy as we build on our aim towards no longer treating to progression but treating to cure.” About MajesTEC-5 Study MajesTEC-5 ( NCT05695508 ) is an ongoing, Phase 2 study of teclistamab and talquetamab, evaluating the safety and efficacy of combination regimens in participants with transplant-eligible NDMM. 4 About MajesTEC-4 Study MajesTEC-4 ( NCT05243797 ) is an ongoing, multicentre, randomised, open-label, Phase 3 study of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone in participants with NDMM as maintenance therapy following ASCT. 5 About MajesTEC-7 Study MajesTEC-7 ( NCT05552222 ) is a Phase 3 randomised study comparing teclistamab in combination with daratumumab SC and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab SC and lenalidomide (Tal-DR) versus daratumumab SC, lenalidomide, and dexamethasone (DRd) in participants with NDMM who are either ineligible or not intended for ASCT as initial therapy. 3 About Teclistamab Teclistamab is an off-the-shelf (or ready to use) bispecific antibody. 6 Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body's immune system to fight the cancer. Teclistamab is currently being evaluated in several combination studies. 6 , 7 , 8 , 9 , 10 Teclistamab received European Commission (EC) approval in August 2022 for the treatment of patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. 11 In August 2023, the EC approved a Type II variation application for teclistamab, providing the option for a reduced dosing frequency of 1.5mg/kg every two weeks in patients who have achieved a complete response (CR) or better for a minimum of six months. 12 For a full list of adverse events and information on dosage and administration, contraindications and other precautions when using teclistamab, please refer to the Summary of Product Characteristics . In line with European Medicine Agency (EMA) regulations for new medicines and those given conditional approval, teclistamab is subject to additional monitoring. About Daratumumab and Daratumumab SC Johnson & Johnson is committed to exploring the potential of daratumumab for patients with multiple myeloma (MM) across the spectrum of the disease. In August 2012 , Janssen Biotech, Inc., a Johnson & Johnson company and Genmab A/S entered a worldwide agreement, which granted Johnson & Johnson an exclusive licence to develop, manufacture and commercialise daratumumab. Since launch, daratumumab has become a foundational therapy in the treatment of MM, having been used in the treatment of more than 585,000 patients worldwide. 13 Daratumumab is the only CD38-directed antibody approved to be given subcutaneously to treat patients with MM. 14 Daratumumab SC is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE ® drug delivery technology. 15 CD38 is a surface protein that is present in high numbers on MM cells, regardless of the stage of disease. 16 Daratumumab binds to CD38 and inhibits tumour cell growth causing myeloma cell death. 8 Daratumumab may also have an effect on normal cells. 17 Data across ten Phase 3 clinical trials, in both the frontline and relapsed settings, have shown that daratumumab-based regimens resulted in significant improvement in progression-free survival and/or overall survival. 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 For further information on daratumumab, please see the Summary of Product Characteristics at: https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf . About Multiple Myeloma MM is an incurable blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow. 27 , 28 In MM, these malignant plasma cells change and grow out of control. In the European Union, it is estimated that more than 35,000 people were diagnosed with MM in 2022, and more than 22,700 patients died. 29 While some patients with MM initially have no symptoms, others can have common symptoms of the disease, which can include bone fracture or pain, low red blood cell counts, tiredness, high calcium levels or kidney failure. 30 About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.innovativemedicine.jnj.com/emea . Follow us at www.linkedin.com/company/jnj-innovative-medicine-emea . Janssen-Cilag International NV, Janssen Pharmaceutica NV, Janssen-Cilag Limited, Janssen Biotech, Inc., and Janssen Research & Development, LLC are Johnson & Johnson companies. Cautions Concerning Forward-Looking Statements This press release contains "forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding product development and the potential benefits and treatment impact of teclistamab and daratumumab SC. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialise, actual results could vary materially from the expectations and projections of Janssen Pharmaceutica NV, Janssen-Cilag Limited, Janssen Biotech, Inc., Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements” and "Item 1A. Risk Factors,” and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at http://www.sec.gov/ , http://www.jnj.com/ or on request from Johnson & Johnson. None of Janssen Pharmaceutica NV, Janssen-Cilag Limited, Janssen Biotech, Inc., Janssen Research & Development, LLC nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments. * Marc S. Raab, M.D., has provided consulting, advisory, and speaking services to Johnson & Johnson; he has not been paid for any media work. 2 Zamagni E et al. 494 Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the MajesTEC-4/EMN30 Trial. Oral presentation. American Society of Hematology (ASH) Annual Meeting; December 7-10, 2024. 3 A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (MajesTEC-7). Available at: https://classic.clinicaltrials.gov/ct2/show/NCT05552222 . Last accessed December 2024. 4 GMMG-HD10 /​ DSMM-XX /​ 64007957MMY2003, MajesTEC-5 (HD10/DSMMXX). Available at: https://clinicaltrials.gov/study/NCT05695508 . Last accessed December 2024. 5 Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4). Available at: https://clinicaltrials.gov/study/NCT05243797 . Last accessed December 2024. 6 European Medicines Agency. TECVAYLI Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf . Last accessed: December 2024. 7 ClinicalTrials.gov. A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (MajesTEC-2). Available at: https://clinicaltrials.gov/ct2/show/NCT04722146 . Last accessed: December 2024. 8 ClinicalTrials.gov. A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT04586426 . Last accessed: December 2024. 9 ClinicalTrials.gov. A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma. Available at: https://clinicaltrials.gov/ct2/show/NCT04108195 . Last accessed: December 2024. 10 ClinicalTrials.gov. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (TecDara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-3). Available at: https://clinicaltrials.gov/ct2/show/NCT05083169 . Last accessed: December 2024. 11 Janssen.com. Janssen Marks First Approval Worldwide. Available at: https://www.janssen.com/emea/sites/www_janssen_com_emea/files/teclistamab_ec_approval_release.pdf . Last accessed: December 2024. 12 Janssen.com. European Commission Approves Reduced Dosing Frequency for Janssen's Bispecific Antibody TECVAYLI®▼ (teclistamab). Available at: https://www.jnj.com/media-center/press-releases/european-commission-approves-reduced-dosing-frequency-for-janssens-bispecific-antibody-tecvayli-teclistamab . Last accessed: December 2024. 13 Data on file. RF-439245. October 2024. 14 Sonneveld P et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2024; 390:301-313. 15 Janssen EMEA. European Commission Grants Marketing Authorisation for DARZALEX ® (Daratumumab) Subcutaneous Formulation for All Currently Approved Daratumumab Intravenous Formulation Indications. Available at: www.businesswire.com/news/home/20200604005487/en/European-Commission-GrantsMarketingAuthorisation-for-DARZALEX%C2%AE%E2%96%BC-daratumumab-SubcutaneousFormulation-for-all-CurrentlyApproved-Daratumumab-Intravenous-Formulation-Indications . Last accessed: December 2024. 16 European Medicines Agency. DARZALEX (daratumumab) Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/darzalex-epar-product-information_en.pdf . Last accessed: December 2024. 17 Moreau P et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 2019;394(10192):29-38. 18 Facon T et al. MAIA Trial Investigators. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med 2019;380(22):2104-2115. 19 Mateos MV et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. The Lancet 2020;395:P132-141. 20 Dimopoulos MA et al. APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(6):801-812. 21 Palladini G et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood 2020;2;136(1):71-80. 22 Chari A et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 2017;130(8):974-981. 23 Bahlis NJ et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 2020;34(7):1875-1884. 24 Mateos MV et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 2020;20(8):509-518. 25 Sonneveld P et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2024;390(4):301-313. DOI: 10.1056/NEJMoa23120 26 Usmani S Z et al. Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study. Oral presentation. 21 st International Myeloma Society (IMS) Annual Meeting; September 25-28, 2024. 27 American Society of Clinical Oncology. Multiple myeloma: introduction. Available at: https://www.cancer.net/cancer-types/multiple-myeloma/introduction . Last accessed: December 2024. 28 Abdi J et al. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget 2013;4(12):2186-2207. 29 European Cancer Information System. Estimates of cancer incidence and mortality in 2022, by country. Multiple myeloma. Available at: https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1,2$3-51$6-0,85$5-2022,2022$7-7$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 . Last accessed: December 2024. 30 American Cancer Society. Multiple myeloma: early detection, diagnosis and staging. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8740.00.pdf . Last accessed: December 2024. CP-492505 December 2025 CONTACT: Media contact: Jenni Mildon [email protected] +44 7920 418 552 Investor contact: Lauren Johnson [email protected]I'm a Celebrity 2024 live: Ant admits being 'unprofessional' as Dean takes on trial

China-Linked Hackers Breached 8 US Telecom Companies, White House SaysA man accused of setting a woman on fire inside a New York City subway train and then watching her die after she was engulfed in flames has made an initial court appearance and will remain in custody. Sebastian Zapeta, 33, who federal immigration officials said is a Guatemalan citizen who entered the US illegally, was arraigned in Brooklyn criminal court. He appeared briefly before a judge and wore a white jumpsuit over a weathered black hooded sweatshirt. He did not speak. He will remain jailed ahead of his next court date on Friday. The apparently random attack occurred on Sunday morning on a stationary F train at the Coney Island station in Brooklyn. Police said on Tuesday that identification of the victim was still “pending at this time”. Authorities say Zapeta approached the woman, who was sitting motionless in the train car and may have been sleeping, and used a lighter to set her clothing on fire. The woman quickly became engulfed in flames, while the suspect then sat at a bench on the subway platform and watched, according to police. Video posted to social media appeared to show the woman standing inside the train ablaze as some people look on from the platform, and at least one officer walks by. NYPD chief of transit Joseph Gulotta said that several officers had responded to the fire and one stayed to keep the crime scene “the way it’s supposed to be” while the others went to get fire extinguishers and transit workers. They were eventually able to douse the fire, but “unfortunately, it was too late”, Police Commissioner Jessica Tisch said — the woman was pronounced dead at the scene. During Zapeta’s court hearing on Tuesday, Assistant District Attorney Ari Rottenberg said Zapeta at one point fanned the flames on the woman using his shirt. He said a 911 call from a subway rider helped identify Zapeta. Mr Rottenberg added that under interrogation Zapeta claimed he did not know what happened, noting that he consumes alcohol. But he alleged that Zapeta identified himself to interrogators in images related to the attack. Zapeta was taken into custody on Sunday afternoon while riding a train on the same subway line after police got a tip from some teenagers who recognised him from images circulated by the police. A Brooklyn address for Zapeta released by police matches a shelter that provides housing and substance abuse support. The shelter did not immediately respond to a request for comment. Federal immigration officials said Zapeta had been previously deported in 2018 but at some point reentered the US illegally. The crime — and the graphic video of it that ricocheted across social media — deepened a growing sense of unease among some New Yorkers about the safety of the subway system in a city where many residents take the subway multiple times each day.What's next for the 2025 real estate market? We may see better prices and more inventory

Christmas presents donated by the people in the were distributed to young children in state hospitals on Tuesday. The presents were collected around a Christmas tree on Castille Square in the past few days. The prime minister and his wife Lydia Abela were among those who distributed them on Christmas Eve at Mater Dei Hospital and Sir Anthony Mamo Oncology Centre. They were accompanied by Health Minister Jo Etienne Abela. The prime minister also met the directors of Puttinu Cares and thanked them for their work for sick children. He promised them the country's support. You can unsubscribe at any time by clicking the link in the footer of our emails. We use as our marketing platform. By subscribing, you acknowledge that your information will be transferred to Mailchimp for processing.Warning over hiking apps after 'virtually identical' rescues on Vancouver North Shore